What's in Betta Pharmaceuticals Co., Ltd.'s pipeline?

Betta Pharmaceuticals Co., Ltd. has 30 drugs in our index: 4 marketed, 0 filed, 1 in Phase 3, 9 in Phase 2, 16 in Phase 1.

Which companies overlap with Betta Pharmaceuticals Co., Ltd.'s portfolio?

Top competitors by shared drug class: Sun Yat-sen University, Beijing InnoCare Pharma Tech Co., Ltd., Pfizer, AstraZeneca, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/betta-pharmaceuticals-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Betta Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Betta Pharmaceuticals Co., Ltd. pipeline: 4 marketed, 0 filed, 1 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 1 Phase 3 9 Phase 2 16 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Maintenance icotinib	Maintenance icotinib	marketed	EGFR tyrosine kinase inhibitor (TKI)	EGFR (epidermal growth factor receptor)	Oncology
Icotinib plus WBRT	Icotinib plus WBRT	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)	Oncology
Sequential and maintenance icotinib	Sequential and maintenance icotinib	marketed	EGFR tyrosine kinase inhibitor	EGFR	Oncology
Sequential Icotinib Plus Chemotherapy	Sequential Icotinib Plus Chemotherapy	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)	Oncology
BPI-16350	BPI-16350	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology

Therapeutic area mix

Oncology · 7
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sun Yat-sen University · 2 shared drug classes
Beijing InnoCare Pharma Tech Co., Ltd. · 2 shared drug classes
Pfizer · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Bayer · 1 shared drug class
Allist Pharmaceuticals, Inc. · 1 shared drug class
Beta Pharma Shanghai · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Betta Pharmaceuticals Co., Ltd.:

Cite this brief

Drug Landscape (2026). Betta Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/betta-pharmaceuticals-co-ltd. Accessed 2026-06-10.